UBS Group
NTLA icon

UBS Group’s Intellia Therapeutics NTLA Stock Holding History

UBS Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.97M Sell
293,588
-275,184
-48% -$3.85M ﹤0.01% 4165
2026
Q1 		$7.29M Buy
568,772
+190,588
+50% +$2.43M ﹤0.01% 3672
2025
Q4 		$3.4M Sell
378,184
-117,692
-24% -$1.62M ﹤0.01% 4419
2025
Q3 		$8.56M Buy
495,876
+255,167
+106% +$3.14M ﹤0.01% 3481
2025
Q2 		$2.26M Buy
+240,709
New +$1.98M ﹤0.01% 4686
2024
Q4 		– Sell
-18,648
Closed -$383K – 10248
2024
Q3 		$383K Buy
+18,648
New +$430K ﹤0.01% 5419

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

UBS Group's NTLA Position: Q2 2026 in Review

UBS Group reduced its Intellia Therapeutics (NTLA) stake by 20% in Q2 2026, selling an estimated $7.51M and leaving 2,152,912 shares worth $36.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2068.

UBS Group first reported a position in NTLA in Q2 2016 and has held it in 41 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • UBS Group held 2,152,912 shares of Intellia Therapeutics worth $36.4M as of Q2 2026.
  • UBS Group sold 536,574 Intellia Therapeutics shares in Q2 2026, an estimated $7.51M.
  • Intellia Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2068 holding.
  • UBS Group first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 41 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.